Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathryn Dawson

Interventional Cardiology Portland, OR Medical Doctor

NPI 1477997724 CMS profile 6943606

9427 Sw Barnes Rd Ste 495, Portland, OR 97225

Open in the dashboard

General payments

$56,950

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Dawson of Portland, OR is reported in the CMS Open Payments database as having received $56,950 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,981 79
2024 General $1,560 18
2023 General $3,580 53
2022 General $621 7
2021 General $20,107 2
2019 General $100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Dawson
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Kathryn Dawson were reported at $30,981. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Kathryn Dawson Interventional Cardiology median Middle half National median
2019 $100 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $20,107 $677 $233–$1,827 $132
2022 $621 $978 $333–$2,724 $149
2023 $3,580 $1,136 $382–$2,986 $160
2024 $1,560 $1,181 $395–$3,326 $164
2025 $30,981 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $28,347 29 payments
  2. Boston Scientific Corporation $21,846 26 payments
  3. Medtronic, Inc. $2,578 34 payments
  4. Asahi Intecc USA, Inc. $1,274 37 payments
  5. Teleflex LLC $1,074 10 payments
  6. Shockwave Medical, Inc $713 6 payments
  7. Abiomed $655 12 payments
  8. Arrow International, Inc. $173 1 payment
  9. Biotronik Inc. $118 1 payment
  10. Reflow Medical Inc $81 1 payment
  11. Other $91 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,500 2 payments
  2. Grant $20,000 1 payment
  3. Food and Beverage $7,752 124 payments
  4. Travel and Lodging $5,691 32 payments
  5. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. OPTIS $28,347 29 payments
  2. GENERAL ATHERECTOMY $20,000 1 payment
  3. RESOLUTE ONYX $1,779 20 payments
  4. AVVIGO Guidance System $1,057 15 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $605 5 payments
  6. GUIDELINER $442 3 payments
  7. MANTA $417 3 payments
  8. Asahi Coronary Wires $414 11 payments
  9. ASAHI PTCA Guide Wire $412 19 payments
  10. ONYX FRONTIER $296 5 payments
  11. Other $2,212 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

177

Median for Interventional Cardiology: 2,236

Drug cost

$1,521

Median for Interventional Cardiology: $380,412

Branded share of claims

43.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 34 $545
Clopidogrel Clopidogrel Bisulfate Brand 56 $274
Metoprolol Succinate Generic 25 $227
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 21 $197
Rosuvastatin Calcium Generic 11 $116
Losartan Potassium Generic 18 $102
Amlodipine Besylate Generic 12 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$62,550

Medicare's payments for the services billed

Medicare patients

130

Average age 74

Services billed

434

44 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 65%
Diabetes 49%
Chronic kidney disease 42%
Arthritis 40%
Atrial fibrillation 38%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record